-+ 0.00%
-+ 0.00%
-+ 0.00%

Cingulate's Data From Lead ADHD Candidate CTx-1301 Selected For Podium Presentation At AACAP Annual Meeting In Chicago

Benzinga·10/23/2025 20:48:34
Listen to the news

Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™) drug-delivery platform, today announced that data from its lead ADHD candidate CTx-1301 (dexmethylphenidate HCl) has been selected for podium presentation at the American Academy of Child and Adolescent Psychiatry (AACAP) Annual Meeting in Chicago. This recognition highlights growing scientific interest in CTx-1301, a once-daily, extended-release formulation designed to simplify treatment for millions living with ADHD.

The Phase 3 data will be presented by Ann Childress, M.D., a leading ADHD specialist and past President of the American Professional Society of ADHD and Related Disorders (APSARD). Her presentation, "Efficacy and Safety of CTx-1301 in Pediatric Subjects With ADHD," is scheduled for Friday, October 24, 2025.